Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners


Other names: Oncimmune | Oncimmune LLC | Oncimmune LTD | Oncimmune Americas | Protagen Diagnostics AG
Related tests:


Oncimmune partners with Siemens Healthineers on lung cancer therapy (Market Screener)
"Oncimmune Holdings PLC on Friday said that it has collaborated with Siemens Healthineers AG, a Frankfurt-based medical technology company, in order to improve malignancy risk assessment in lung cancer....The collaboration will bring together Oncimmune's EarlyCDT Lung blood test with Siemens Healthineers' AI-Rad Companion Chest CT, an AI-powered radiology assistant that supports radiologists by performing automatic post-processing, quantifying and interpreting data....The collaboration will access data from the Early Detection of Cancer of the Lung Scotland trial, the large randomised study into the utility of EarlyCDT Lung in asymptomatic screening."
Licensing / partnership • Clinical data
EarlyCDT® Lung test approved by Ministry of Health for Aragon, Spain and set to be adopted in the University Hospital Miguel Servet, Zaragoza (Oncimmune Press Release)
"Oncimmune Holdings plc...notes the Regional Ministry of Health for Aragon, Spain has announced that the Company's Early CDT® Lung blood test is to be adopted by the Thoracic Surgery Unit of the University Hospital Miguel Servet, Zaragoza, for use on solitary pulmonary nodules. This approval follows the issuing of a favourable assessment and report by the Evaluation Committee of the Aragonese Health System having met the necessary criteria with regards to efficacy and safety."
Non-US regulatory
Agreement signed with major cancer center to profile patients in immuno-oncology trial (Copia Digital)
“Oncimmune Holdings plc…announces it has signed an autoantibody profiling contract with Dana-Farber Cancer Institute…Under this agreement, Oncimmune will be utilising its proprietary biomarker discovery engine, SeroTagTM, to identify autoantibodies that can be predictive of patient response or associated with resistance to checkpoint inhibitors (‘CPIs’) and chemotherapy used in Dana-Farber led studies or therapy using atezolizumab, nivolumab, pembrolizumab, durvalumab and cisplatin-based chemotherapy. In addition, SeroTag will be used for identifying autoantibodies that can be predictive of immune-related adverse events ‘irAEs’) in response treatment. The project is scheduled to complete by the end of 2021.”
Licensing / partnership
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab)
Return of China rights to EarlyCDT product portfolio (IR Solutions, Q4 Europe)
"Oncimmune Holdings plc...today announces that it has successfully agreed to acquire the intellectual property (IP) and distribution rights for the EarlyCDT® technology in the People's Republic of China (PRC) and Hong Kong (HK) from Genostics Company Limited (Genostics), allowing the Company to pursue the optimum route to market in this important territory...The Asia-specific lung panel has been used in a multi-centre study, previously announced on 10 May 2019, and which is now due to complete in China in H1 2021. Data from this study are intended to be used to support approval by the China National Medical Products Administration (NMPA) for the use of the Asia-specific lung cancer test in the PRC." "
EarlyCDT® Lung blood test launch into the NHS (IR Solutions, Q4 Europe)
"Oncimmune Holdings plc...today announces that it has signed a commercial contract to supply its EarlyCDT Lung blood test to NHS Norfolk & Waveney Clinical Commissioning Group ('Norfolk & Waveney'). Additionally, the Company has also signed a commercial contract to supply EarlyCDT Lung blood test into the NHS Lung Health Check Programmes in Wessex and Yorkshire as part of the iDx-LUNG evaluation programme. Following in-depth due diligence by the NHS, the Company has also been notified that The National Institute for Health and Care Excellence (NICE) has selected the EarlyCDT Lung blood test for Diagnostics Assessment Guidance...Under this commercial contract, Norfolk & Waveney will be evaluating the use of the EarlyCDT Lung blood test in a clinical setting."
Licensing / partnership • Launch Europe